Ruxolitinib
Back to searchMolecule Structure
Scientific Name
Ruxolitinib
Description of the Drug
Ruxolitinib is a kinase inhibitor used to treat various types of myelofibrosis, polycythemia vera in patients who have not responded to or cannot tolerate hydroxyurea, and to treat graft-versus-host disease in cases that are refractory to steroid treatment.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB08877
http://www.drugbank.ca/drugs/DB08877
Brand Name(s)
Jakavi
Company Owner(s)
Incyte Corp
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Tyrosine-protein kinase JAK2 | SINGLE PROTEIN | INHIBITOR | CHEMBL2971 |
Tyrosine-protein kinase JAK1 | SINGLE PROTEIN | INHIBITOR | CHEMBL2835 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL171319 | SCHEMBL16546708 | |
PharmGKB | PA166123386 | ||
DrugBank | DB08877 | ||
PubChem: Thomson Pharma | 81071277 | ||
PubChem | 25126798 | ||
LINCS | LSM-1139 | ||
Nikkaji | J2.740.099J | ||
PDBe | RXT | ||
BindingDB | 50355501 | ||
EPA CompTox Dashboard | DTXSID10240930 | ||
DrugCentral | 4190 | ||
Brenda | 39793 | 19116 | |
ChemicalBook | CB02499581 | ||
Guide to Pharmacology | 5688 | ||
rxnorm | JAKAFI | RUXOLITINIB PHOSPHATE | RUXOLITINIB |
ChEBI | 66919 | ||
ZINC | ZINC000043207851 |